Chartwell Investment Partners LLC lifted its stake in Boston Scientific Co. (NYSE:BSX) by 0.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 172,545 shares of the medical equipment provider’s stock after purchasing an additional 267 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Boston Scientific were worth $6,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc raised its stake in shares of Boston Scientific by 4.4% during the 1st quarter. Legal & General Group Plc now owns 9,168,985 shares of the medical equipment provider’s stock worth $299,718,000 after purchasing an additional 387,556 shares in the last quarter. APG Asset Management N.V. lifted its holdings in Boston Scientific by 93.9% in the 1st quarter. APG Asset Management N.V. now owns 1,000,864 shares of the medical equipment provider’s stock worth $32,658,000 after purchasing an additional 484,800 shares during the last quarter. AXA boosted its position in Boston Scientific by 14.1% during the first quarter. AXA now owns 1,168,594 shares of the medical equipment provider’s stock worth $38,131,000 after purchasing an additional 144,678 shares during the period. Anchor Capital Advisors LLC grew its holdings in Boston Scientific by 0.3% during the first quarter. Anchor Capital Advisors LLC now owns 1,520,368 shares of the medical equipment provider’s stock valued at $49,610,000 after purchasing an additional 4,414 shares during the last quarter. Finally, Capital International Investors raised its position in shares of Boston Scientific by 3.3% in the first quarter. Capital International Investors now owns 207,413 shares of the medical equipment provider’s stock valued at $6,768,000 after purchasing an additional 6,590 shares during the period. Institutional investors and hedge funds own 89.97% of the company’s stock.
Several research firms recently issued reports on BSX. CSFB upped their price objective on shares of Boston Scientific from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Thursday, April 30th. Stifel Nicolaus raised their price target on Boston Scientific from $45.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday. BTIG Research reiterated a “buy” rating and issued a $44.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 29th. SunTrust Banks decreased their target price on Boston Scientific from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Finally, Citigroup lifted their price target on Boston Scientific from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $44.71.
NYSE:BSX opened at $38.57 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.80 and a current ratio of 1.21. The company has a 50-day moving average of $36.11 and a 200-day moving average of $37.19. Boston Scientific Co. has a 52 week low of $24.10 and a 52 week high of $46.62. The company has a market capitalization of $53.97 billion, a price-to-earnings ratio of 13.68, a PEG ratio of 3.94 and a beta of 0.92.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.12. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.68 billion. Boston Scientific had a net margin of 39.18% and a return on equity of 13.68%. The company’s quarterly revenue was down 23.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.39 earnings per share. Sell-side analysts forecast that Boston Scientific Co. will post 0.93 EPS for the current year.
In related news, EVP David A. Pierce sold 2,170 shares of the firm’s stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $38.00, for a total transaction of $82,460.00. Following the completion of the transaction, the executive vice president now owns 9,401 shares in the company, valued at approximately $357,238. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is owned by company insiders.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Further Reading: What is the Euro STOXX 50 Index?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.